Healthcare / Diagnostics & ResearchParis
$26.95
+0.35 (+1.32%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $11.4M · quality 36.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
65/100
B
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$595M
P/E
42.1x
↑EV/EBITDA
15.3x
↑ROE
6.8%
↑Gross Margin
64.0%
↑Debt/Equity
0.71
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.6%
FCF CAGR
—
FCF margin
5.5%
FCF / Net income
0.90x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $228.5M · net income $14.0M · FCF $12.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $228.5M | $228.5M | $210.1M | $206.6M | $194.3M |
| Net Income | $14.0M | $14.0M | $5.7M | $7.1M | $11.4M |
| EBITDA | $44.3M | $44.3M | $31.1M | $27.7M | $32.7M |
| EPS | 0.64 | 0.64 | 0.26 | 0.32 | 0.51 |
| Gross Margin | 64.0% | 64.0% | 62.3% | 62.2% | 62.4% |
| Operating Margin | 11.2% | 11.2% | 7.1% | 8.9% | 8.4% |
| Net Margin | 6.1% | 6.1% | 2.7% | 3.4% | 5.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.71 | 0.71 | 0.81 | 0.75 | 0.59 |
| Current Ratio | 2.47 | 2.47 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $12.6M | $12.6M | $11.4M | $-4.9M | $-28.0M |
| Returns | |||||
| ROE | 6.8% | 6.8% | 2.9% | 3.7% | 5.9% |
| Valuation | |||||
| P/E | 42.11 | 42.11 | 40.00 | 38.00 | 33.02 |
| EV/EBITDA | 15.30 | 15.30 | 10.26 | 13.00 | 13.08 |
| P/B | 2.88 | 2.88 | 1.16 | 1.40 | 1.94 |
| Growth & Yield | |||||
| Revenue Growth | 8.8% | 8.8% | 1.7% | 6.3% | — |
| EPS Growth | 146.2% | 146.2% | -18.8% | -37.3% | — |
| Dividend Yield | 1.4% | 1.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
55.2%
EPS terminal req.
$2.39
Spread vs growth
91.0%
5Y implied EPS CAGR
35.2%
EPS terminal req.
$2.89
Spread vs growth
110.9%
10Y implied EPS CAGR
22.0%
EPS terminal req.
$4.66
Spread vs growth
124.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+93.2%
Start / end P/E
54.0x → 42.1x
EPS bridge
0.26 → 0.64
Residual
-32.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.